Daily Journal Staff Writer
WASHINGTON - In a case that could rock the growing personalized medicine industry, the U.S. Supreme Court weighed Wednesday whether a San Diego laboratory's diagnostic test should be patented.
The test at issue, developed by Prometheus Laboratories Inc., measures the rate at which a patient metabolizes a drug used to treat autoimmune disorders to help doctors determine the proper dosage for th...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In